Kinaset Therapeutics Debuts Positive Outcomes Data from Phase 1b Study of KN-002 at the 2024 American Thoracic Society (ATS) International Conference
Kinaset to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Kinaset Therapeutics to Present KN-002 Phase 1 Clinical Study Outcomes at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced an upcoming presentation at the ATS 2023 Respiratory Innovation Summit being held in Washington D.C. May 19-20, 2023. Robert Clarke, PhD, Chief Executive Officer of Kinaset, will deliver an oral and poster presentation on the latest clinical progress of Kinaset’s lead candidate, KN-002, a novel, pan-JAK inhibitor being advanced for the treatment of moderate to severe asthma.
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, announced the appointment of Dr. Chris O’Brien as the Company's Chief Medical Officer.
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a biopharmaceutical company developing a next generation anti-inflammatory therapy to treat patients with severe asthma, today announced that the first 24 participants have been dosed in its Phase 1b placebo-controlled study. This trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of KN-002, a novel and potent inhibitor of all Janus kinase (JAK) isoforms (i.e. JAK1, JAK2, JAK3, TYK2) that is formulated as a dry powder for inhaled delivery to the lung.